[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 338, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1968759, "exercisedValue": 0, "unexercisedValue": 5090000}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 670578, "exercisedValue": 0, "unexercisedValue": 3031375}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 41.89, "open": 41.62, "dayLow": 41.19, "dayHigh": 43.15, "regularMarketPreviousClose": 41.89, "regularMarketOpen": 41.62, "regularMarketDayLow": 41.19, "regularMarketDayHigh": 43.15, "payoutRatio": 0.0, "beta": 2.301, "trailingPE": 286.6, "forwardPE": 44.319588, "volume": 4345596, "regularMarketVolume": 4257486, "averageVolume": 2585120, "averageVolume10days": 3420000, "averageDailyVolume10Day": 3420000, "bid": 36.47, "ask": 43.14, "bidSize": 1, "askSize": 6, "marketCap": 6752482816, "fiftyTwoWeekLow": 12.93, "fiftyTwoWeekHigh": 43.15, "priceToSalesTrailing12Months": 20.524014, "fiftyDayAverage": 33.1208, "twoHundredDayAverage": 26.566175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 6186688512, "profitMargins": 0.07107, "floatShares": 134539735, "sharesOutstanding": 157071008, "sharesShort": 25952803, "sharesShortPriorMonth": 26879160, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.16520001, "heldPercentInsiders": 0.093789995, "heldPercentInstitutions": 0.62813, "shortRatio": 14.83, "shortPercentOfFloat": 0.1824, "impliedSharesOutstanding": 157071008, "bookValue": 1.544, "priceToBook": 27.843266, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": 23383000, "trailingEps": 0.15, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 18.804, "enterpriseToEbitda": 147.313, "52WeekChange": 1.7399619, "SandP52WeekChange": 0.086116076, "quoteType": "EQUITY", "currentPrice": 42.99, "targetHighPrice": 55.0, "targetLowPrice": 10.0, "targetMeanPrice": 42.83333, "targetMedianPrice": 48.0, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 311000000, "totalCashPerShare": 2.141, "ebitda": 41997000, "totalDebt": 254380000, "quickRatio": 4.854, "currentRatio": 6.246, "totalRevenue": 329004000, "debtToEquity": 114.398, "revenuePerShare": 2.264, "returnOnAssets": 0.05777, "returnOnEquity": 0.122150004, "grossProfits": 290518016, "freeCashflow": -62020876, "operatingCashflow": -40517000, "revenueGrowth": 1.46, "grossMargins": 0.88302004, "ebitdaMargins": 0.12765001, "operatingMargins": 0.27683002, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1742601364, "regularMarketTime": 1742587201, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.6259305, "regularMarketPrice": 42.99, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": 0.0, "postMarketPrice": 42.99, "postMarketChange": 0.0, "regularMarketChange": 1.1000023, "regularMarketDayRange": "41.19 - 43.15", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2585120, "fiftyTwoWeekLowChange": 30.060001, "fiftyTwoWeekLowChangePercent": 2.324826, "fiftyTwoWeekRange": "12.93 - 43.15", "fiftyTwoWeekHighChange": -0.15999985, "fiftyTwoWeekHighChangePercent": -0.0037079917, "fiftyTwoWeekChangePercent": 173.99619, "earningsTimestamp": 1736861400, "earningsTimestampStart": 1745929800, "earningsTimestampEnd": 1746448200, "earningsCallTimestampStart": 1741008600, "earningsCallTimestampEnd": 1741008600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.15, "epsForward": 0.97, "epsCurrentYear": 1.05911, "priceEpsCurrentYear": 40.590683, "fiftyDayAverageChange": 9.869202, "fiftyDayAverageChangePercent": 0.29797596, "twoHundredDayAverageChange": 16.423826, "twoHundredDayAverageChangePercent": 0.6182232, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-22"}]